Literature DB >> 31055959

[A case of primary leiomyosarcoma originating from the inferior vena cava].

Csaba Weninger1,2, Edit Várady1, Giyab Omar1, Imre Szabó3, Tamás Tornóczky4.   

Abstract

The venous invasion from intraabdominal and retroperitoeal tumors (e.g., liver and kidney) is relatively frequent. Primary vascular (venous) tumors are uncommon. The authors review the case of a 67-year-old woman, who was admitted to the hospital in a poor general condition with jaundice. Laboratory findings indicated hepatic and renal insufficiency. Abdominal ultrasound detected a large retroperitoneal mass which was suspected to be of uterine origin. Abdominal CT showed a retroperitoneal mass that invaded the inferior vena cava, but there was no sign of primary intraabdominal or pelvic tumor. Due to the poor general condition of the patient, surgery was not performed. The patient died in some days after admission. Autopsy revealed a primary leiomyosarcoma of the inferior vena cava. Based on the literature data, primary leiomyosarcoma of the inferior vena cava is extremely rare. Leiomyosarcoma of the inferior vena cava can cause various symptoms, depending on the involved segment of the vein. Surgical intervention can be performed in early stages of the disease. In uncertain retroperitoneal tumors involving the inferior vena cava, radiologists should think of the possibility of tumor with vascular origin. Orv Hetil. 2019; 160(19): 756-761.

Entities:  

Keywords:  computed tomography; inferior vena cava; leiomyosarcoma; számítógépes rétegvizsgálat (CT); vena cava inferior

Mesh:

Year:  2019        PMID: 31055959     DOI: 10.1556/650.2019.31379

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  1 in total

1.  Case Report: A case of uterine leiomyosarcoma metastasized to the vena cava, excised with the aid of preoperative CT three-dimensional imaging.

Authors:  Ling Long; Ling Zhou; Demei Ying; Yan Huang; Juan Yang; Lu Zhou; Sufen Li; Xuan He; Rongkai Xie
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.